MabPharm Ltd (HKG: 2181), a biosimilar specialist in monoclonal antibody (mAb) based in Taizhou, has announced that it has received market approval for CMAB807, a biosimilar version of Johnson & Johnson (J&J)’s Remicade (infliximab), in Peru. The approval encompasses all six indications, which include adult ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, adult and childhood Crohn’s disease, fistula Crohn’s disease, and psoriasis.
Infliximab, a tumor necrosis factor (TNF) inhibitor, is utilized in the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It received approvals in the US, Europe, and China in 1998, 1999, and 2007, respectively. Notably, CMAB008, which is included in China’s National Reimbursement Drug List (NRDL), is the first biosimilar of its kind in the country.- Flcube.com
